|
WO2009091531A2
(en)
*
|
2008-01-16 |
2009-07-23 |
The General Hospital Corporation |
Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
|
|
JP5977229B2
(ja)
|
2010-05-05 |
2016-08-24 |
プロリンクス リミテッド ライアビリティ カンパニー |
巨大分子共役体からの徐放
|
|
CA2837979C
(en)
|
2011-06-06 |
2021-03-30 |
Starpharma Pty Ltd |
Dendrimers comprising terminal pharmaceutically active agents and terminal pharmacokinetic modifying agents
|
|
WO2013036857A1
(en)
*
|
2011-09-07 |
2013-03-14 |
Prolynx Llc |
Sulfone linkers
|
|
EP2755691B1
(en)
|
2011-09-07 |
2018-08-22 |
Prolynx LLC |
Hydrogels with biodegradable crosslinking
|
|
WO2013170272A2
(en)
*
|
2012-05-11 |
2013-11-14 |
Alexander Krantz |
Site-specific labeling and targeted delivery of proteins for the treatment of cancer
|
|
US20150352246A1
(en)
*
|
2013-01-22 |
2015-12-10 |
Prolynx Llc |
Sealants having controlled degration
|
|
WO2014205126A1
(en)
|
2013-06-19 |
2014-12-24 |
The Regents Of The University Of California |
Chemical structures for localized delivery of therapeutic agents
|
|
CN106232131A
(zh)
*
|
2013-10-22 |
2016-12-14 |
普洛林克斯有限责任公司 |
生长抑素和其类似物的结合物
|
|
TWI727919B
(zh)
*
|
2013-12-19 |
2021-05-21 |
美商西雅圖遺傳學公司 |
與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
|
|
AU2015229014B2
(en)
|
2014-03-14 |
2019-07-25 |
The Regents Of The University Of California |
TCO conjugates and methods for delivery of therapeutic agents
|
|
US11389511B2
(en)
|
2016-01-08 |
2022-07-19 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with reduced side-effects
|
|
US11311604B2
(en)
|
2016-01-08 |
2022-04-26 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with low NPR-C binding
|
|
EP4162955A1
(en)
|
2016-01-08 |
2023-04-12 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with carrier attachment at the ring moiety
|
|
CA3007976C
(en)
|
2016-01-08 |
2023-09-26 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with large carrier moieties
|
|
NZ743488A
(en)
|
2016-01-08 |
2023-02-24 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with low initial npr-b activity
|
|
US11224661B2
(en)
|
2016-01-08 |
2022-01-18 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with increased NEP stability
|
|
SMT202400423T1
(it)
|
2016-03-01 |
2024-11-15 |
Ascendis Pharma Bone Diseases As |
Profarmaci di pth
|
|
EP3429608A4
(en)
|
2016-03-16 |
2019-12-11 |
Prolynx LLC |
CONJUGATES WITH EXTENDED RELEASE OF EXENATID ANALOG
|
|
WO2018011266A1
(en)
|
2016-07-13 |
2018-01-18 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
NZ751746A
(en)
|
2016-09-29 |
2023-06-30 |
Ascendis Pharma Growth Disorders As |
Combination therapy with controlled-release cnp agonists
|
|
HUE063235T2
(hu)
|
2016-09-29 |
2024-01-28 |
Ascendis Pharma Bone Diseases As |
Adagolási rendszer szabályozott leadású PTH vegyülethez
|
|
SMT202300124T1
(it)
|
2016-09-29 |
2023-05-12 |
Ascendis Pharma Bone Diseases As |
Composti pth con bassi rapporti picco/valle
|
|
HUE070273T2
(hu)
|
2016-09-29 |
2025-05-28 |
Ascendis Pharma Bone Diseases As |
Szabályozott hatóanyag-leadású PTH vegyületek
|
|
JOP20190191A1
(ar)
|
2017-02-22 |
2019-08-08 |
Astrazeneca Ab |
وحدات شجرية علاجية
|
|
EP3600441A1
(en)
|
2017-03-22 |
2020-02-05 |
Genentech, Inc. |
Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
|
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
|
WO2019058374A1
(en)
|
2017-09-19 |
2019-03-28 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
N-METHYLATED CYCLIC PEPTIDES AND PRODRUGS THEREOF
|
|
EP3684417A1
(en)
*
|
2017-09-19 |
2020-07-29 |
Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. |
Lipophilic peptide prodrugs
|
|
MX2020007306A
(es)
|
2018-01-12 |
2020-09-25 |
Prolynx Llc |
Tratamiento sinergico de cancer.
|
|
US11213596B2
(en)
|
2018-03-12 |
2022-01-04 |
Boston Scientific Scimed, Inc. |
Radiocontrast agents, scavenging methods, and scavenging system
|
|
BR112020019639A2
(pt)
|
2018-03-28 |
2021-01-05 |
Ascendis Pharma Oncology Division A/S |
Conjugados de il-2
|
|
US20210008168A1
(en)
|
2018-03-28 |
2021-01-14 |
Ascendis Pharma A/S |
Conjugates
|
|
SMT202500272T1
(it)
|
2018-05-18 |
2025-09-12 |
Ascendis Pharma Bone Diseases As |
Dose iniziale di coniugati di pth
|
|
US12071517B2
(en)
|
2018-07-19 |
2024-08-27 |
Starpharma Pty Ltd. |
Therapeutic dendrimer
|
|
KR102811484B1
(ko)
|
2018-07-19 |
2025-05-22 |
스타파마 피티와이 리미티드 |
치료 덴드리머
|
|
CN113164616A
(zh)
|
2018-09-26 |
2021-07-23 |
阿森迪斯药物股份有限公司 |
可降解的透明质酸水凝胶
|
|
SG11202101971XA
(en)
|
2018-09-26 |
2021-03-30 |
Ascendis Pharma As |
Novel hydrogel conjugates
|
|
EP3856255A1
(en)
|
2018-09-26 |
2021-08-04 |
Ascendis Pharma A/S |
Treatment of infections
|
|
AR116566A1
(es)
|
2018-10-03 |
2021-05-19 |
Novartis Ag |
Administración sostenida de polipéptidos similares a la angiopoyetina 3
|
|
EP3906065B1
(en)
|
2019-01-04 |
2025-04-30 |
Ascendis Pharma Oncology Division A/S |
Prr agonist for use in the treatment of cancer
|
|
AU2020204786A1
(en)
|
2019-01-04 |
2021-06-10 |
Ascendis Pharma Oncology Division A/S |
Induction of sustained local inflammation
|
|
JP2022516314A
(ja)
|
2019-01-04 |
2022-02-25 |
アセンディス ファーマ オンコロジー ディヴィジョン エー／エス |
自然免疫アゴニストのための持続性局所性薬物レベル
|
|
EP3906060A1
(en)
|
2019-01-04 |
2021-11-10 |
Ascendis Pharma Oncology Division A/S |
Conjugates of pattern recognition receptor agonists
|
|
WO2020165087A1
(en)
|
2019-02-11 |
2020-08-20 |
Ascendis Pharma Bone Diseases A/S |
Liquid pharmaceutical formulations of pth conjugates
|
|
CN113423384B
(zh)
|
2019-02-11 |
2024-01-05 |
阿森迪斯药物生长障碍股份有限公司 |
Cnp缀合物的干燥药物制剂
|
|
WO2020206358A1
(en)
*
|
2019-04-05 |
2020-10-08 |
Prolynx Llc |
Improved conjugation linkers
|
|
US20220193253A1
(en)
*
|
2019-04-26 |
2022-06-23 |
Prolynx Llc |
Slow-release cytokine conjugates
|
|
WO2020247151A1
(en)
|
2019-06-05 |
2020-12-10 |
Boston Scientific Scimed, Inc. |
Click chemistry capturable platinum-based antineoplastic agents
|
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
|
CA3143436A1
(en)
*
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
Conjugates of .pi.-electron-pair-donating heteroaromatic nitrogen-comprising compounds
|
|
US20230102309A1
(en)
|
2019-06-21 |
2023-03-30 |
Ascendis Pharma Oncology Division A/S |
Tyrosine kinase inhibitor conjugates
|
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
|
EP3986479A1
(en)
|
2019-06-21 |
2022-04-27 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 conjugates
|
|
JP7784993B2
(ja)
*
|
2019-09-30 |
2025-12-12 |
奥金生命科学（宜興）有限公司 |
タンパク質－巨大分子コンジュゲート及びその使用方法
|
|
EP4090357A1
(en)
|
2020-01-13 |
2022-11-23 |
Ascendis Pharma Bone Diseases A/S |
Hypoparathyroidism treatment
|
|
WO2021224169A1
(en)
|
2020-05-04 |
2021-11-11 |
Ascendis Pharma A/S |
Hydrogel irradiation
|
|
IL298642A
(en)
|
2020-06-03 |
2023-01-01 |
Ascendis Pharma Oncology Div A/S |
il-2 sequences and uses thereof
|
|
TW202219060A
(zh)
|
2020-08-28 |
2022-05-16 |
丹麥商阿森迪斯腫瘤製藥有限公司 |
醣基化il-2蛋白及其用途
|
|
JP2023543265A
(ja)
|
2020-09-28 |
2023-10-13 |
アセンディス ファーマ ボーン ディジージズ エー／エス |
副甲状腺機能低下症を有する患者の身体的及び精神的ウェルビーイングの改善
|
|
WO2022207798A1
(en)
|
2021-04-01 |
2022-10-06 |
Ascendis Pharma A/S |
Use of long-acting growth hormone for treating inflammation-induced diseases
|
|
KR20240082355A
(ko)
|
2021-09-22 |
2024-06-10 |
아센디스 파마 본 디지즈 에이/에스 |
장시간 작용형 pth 화합물 치료
|
|
US20250017948A1
(en)
*
|
2021-10-19 |
2025-01-16 |
The United States Government As Represented By The Department Of Veterans Affairs |
Cannabinoid compositions for gastroesophageal disorders
|
|
IL313041A
(en)
|
2021-12-13 |
2024-07-01 |
Ascendis Pharma Oncology Div A/S |
Cancer treatments with tlr7/8 agonists
|
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
|
CA3249311A1
(en)
|
2022-05-23 |
2023-11-30 |
Ascendis Pharma Growth Disorders A/S |
LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS
|
|
CN114874624B
(zh)
*
|
2022-05-27 |
2023-04-07 |
深圳市博致远科技有限公司 |
一种导热吸波室温固化硅橡胶产品及其制备方法
|
|
JP2025537527A
(ja)
|
2022-11-02 |
2025-11-18 |
アセンディス ファーマ ボーン ディジージズ エー／エス |
２つのｐｔｈ化合物を含むｐｔｈ治療レジメン
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
TW202430223A
(zh)
|
2023-01-05 |
2024-08-01 |
丹麥商阿仙帝斯眼科製藥有限公司 |
用於治療眼部病症之藥物結合物
|
|
TW202434299A
(zh)
|
2023-01-05 |
2024-09-01 |
丹麥商阿仙帝斯製藥公司 |
製造水凝膠微球之方法
|
|
KR20250131829A
(ko)
|
2023-03-06 |
2025-09-03 |
아센디스 파마 에이에스 |
알부민 결합 모이어티를 포함하는 약물 화합물
|
|
AU2024233842A1
(en)
|
2023-03-06 |
2025-09-04 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|
|
AU2024232125A1
(en)
|
2023-03-06 |
2025-08-28 |
Ascendis Pharma A/S |
Compounds of drugs with an albumin binding moiety
|
|
WO2024194300A1
(en)
|
2023-03-20 |
2024-09-26 |
Ascendis Pharma Growth Disorders A/S |
Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
|
|
WO2024231442A1
(en)
|
2023-05-09 |
2024-11-14 |
Ascendis Pharma Oncology Division A/S |
Novel cancer treatments with il-2 conjugates
|
|
AU2024337275A1
(en)
|
2023-09-04 |
2026-02-19 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment of chronic kidney disease
|
|
TW202547452A
(zh)
*
|
2024-03-29 |
2025-12-16 |
美商瑪哈醫療公司 |
可裂解酯類化合物及其用途
|
|
WO2026013138A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Compounds with improved albumin-binding
|
|
WO2026013135A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding reagents
|
|
WO2026013136A1
(en)
|
2024-07-10 |
2026-01-15 |
Ascendis Pharma A/S |
Albumin-binding compounds
|